Bicycle raises £40m to advance pipeline
UK biotech Bicycle Therapeutics has raised an impressive £40 million to help advance its lead candidate, cancer drug BT1718, into the clinic trials later this year.
Read More
Tag: BT1718
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
